SARS-CoV-2 Infection in Women and Children
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 1056
Special Issue Editor
Special Issue Information
Dear Colleagues,
In the context of the COVID-19 pandemic, the world is stepping up efforts to develop vaccines that can help boost herd immunity. Currently approved vaccines require extensive testing to confirm their safety for large-scale use in the general population. However, clinical trials have failed to test the safety and effectiveness of COVID-19 vaccines in people with weakened immune systems, especially in pregnant women.
The SARS-CoV-2 vaccine has been recommended for pregnant women, but survey studies show wildly different results around the world in terms of the willingness to be vaccinated during pregnancy. The cumulative uptake of the SARS-CoV-2 vaccine among pregnant women appears to remain low. A lack of information on the impact of vaccination during pregnancy on fetal safety is one of the most important factors preventing pregnant women from being immunized, thereby preventing herd immunity from being achieved.
Vaccinating as many people as possible is crucial if we are to rebuild a normal way of life. Vaccination campaigns are urgently needed to increase confidence in vaccines to help reduce the spread of infection and possible consequences during pregnancy.
This Special Issue focuses on the immune response of vaccinated pregnant women, the safety and efficacy of COVID-19 vaccination during pregnancy, and the vaccine’s impact on maternal and fetal immune responses. We welcome all types of submissions, including original research, reviews, case reports, etc., for this Special Issue. We look forward to receiving your contributions!
Dr. Narayanaiah Cheedarla
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccines
- COVID-19
- SARS-CoV-2
- vaccination
- pregnant women
- children
- infants
- risk groups
- immune response
- antibodies
